Performance analysis of Drugs Made In America Acquisition II Corp Right (DMIIR)
Annual Return
Since Dec 3, 2025, DMIIR has had an average annual return of -50.00%, underperforming the benchmark SPY, which returned +10.32% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.86% | -12.50% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.29% | +8.33% | -38.46% | +12.50% | -12.11% | +1.13% | +0% | -42.86% | |||||
| 2025 | -12.50% | -12.50% |
Drawdown analysis of Drugs Made In America Acquisition II Corp Right (DMIIR)
The maximum drawdown for the DMIIR was -54.87%, occurring on Jun 24, 2026. This drawdown has not yet recovered.
The current DMIIR drawdown is -50.00%.
Since Dec 3, 2025 DMIIR has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -54.87% | Dec 3, 2025 | 138 | Jun 24, 2026 | Ongoing | Ongoing | Ongoing |